Baxter International Inc

$ 74.33 -0.06 (-0.08%)
Volume: 4,054,375 Avg Vol (1m): 2,861,499
Market Cap $: 37.99 Bil Enterprise Value $: 39.66 Bil
P/E (TTM): 24.78 P/B: 5.07
Earnings Power Value 16.18
Net Current Asset Value -3.62
Tangible Book 6.46
Projected FCF 38.57
Median P/S Value 34.45
Graham Number 20.88
Peter Lynch Value 54.99
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 7/10

Current vs industry vs history
Cash-to-Debt 0.53
Equity-to-Asset 0.50
Debt-to-Equity 0.45
Debt-to-EBITDA 1.35
Interest Coverage 17.19
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.64
DISTRESS
GREY
SAFE
Beneish M-Score -2.66
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 16.16%
WACC 8.9%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 14.37
Net Margin % 14.60
ROE % 18.44
ROA % 9.78
ROC (Joel Greenblatt) % 30.43
3-Year Total Revenue Growth Rate 3.70
3-Year Total EBITDA Growth Rate 24.50
3-Year EPS w/o NRI Growth Rate 60.70

» BAX's 30-Y Financials

Financials (Next Earnings Date: 2019-04-25)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:BAX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS : 339112    SIC : 3841
Compare NAS:ILMN XPAR:EI TSE:4543 OCSE:COLO B NYSE:WAT NYSE:MTD NYSE:RMD NYSE:BDX TSE:7733 NAS:XRAY NYSE:COO XSWX:STMN NAS:HOLX NYSE:STE SZSE:002294 NYSE:WST NYSE:HRC NAS:ICUI NAS:PODD NYSE:CMD
Traded in other countries BTL.Germany 0QK8.UK
Address One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter manufactures medical products across four major business segments. The renal segment (38% of sales) includes hemodialysis and peritoneal dialysis products. Integrated pharmacy solutions (23% of sales) includes nutrition, injectable drugs, and compounding services. IV pumps and solutions make up the fluid systems segment (21% of sales), while biosurgical supplies and anesthetic gases constitute the surgical care segment (13% of sales). Contract manufacturing services round out the roughly remaining 4% of sales.

Ratios

Current vs industry vs history
PE Ratio (TTM) 24.86
Forward PE Ratio 22.68
N/A
PE Ratio without NRI 24.78
Price-to-Owner-Earnings 34.75
PB Ratio 5.07
PS Ratio 3.65
Price-to-Free-Cash-Flow 28.62
Price-to-Operating-Cash-Flow 19.33
EV-to-EBIT 22.21
EV-to-EBITDA 15.43
EV-to-Revenue 3.56
PEG Ratio 1.22
Shiller PE Ratio 18.55
Current Ratio 2.09
Quick Ratio 1.50
Days Inventory 92.59
Days Sales Outstanding 59.44
Days Payable 57.75

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 1.02
Dividend Payout Ratio 0.24
3-Year Dividend Growth Rate (Per Share) -16.90
Forward Dividend Yield % 1.02
N/A
Yield-on-Cost (5-Year) % 0.27
3-Year Share Buyback Rate 1.00

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 11.50
Price-to-Projected-FCF 1.93
Price-to-Median-PS-Value 2.16
Price-to-Peter-Lynch-Fair-Value 1.36
Price-to-Graham-Number 3.57
Earnings Yield (Joel Greenblatt) % 4.50
Forward Rate of Return (Yacktman) % 22.12

More Statistics

Revenue (TTM) (Mil) $ 11,127
EPS (TTM) $ 2.99
Beta 1.16
Volatility % 27.58
52-Week Range $ 61.05 - 82.25
Shares Outstanding (Mil) 511.12

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N